Erratum to: J Gastroenterol (2015) 50:955–961 DOI 10.1007/s00535-015-1046-3
In Table 2, clerical mistakes of the number of patients in low or high than 15.0 ng/ml were made. The number of patients with low than 15.0 ng/ml should be 40, and high should be 25. Table 2 should be shown as follows.
The original version of this article unfortunately contained error in Fig. 4a, the correct Fig. 4a is shown as follows.
Kaplan–Meier analysis of progression-free survival in patients with changes of serum HER2 ECD. a Serum HER2 ECD decline or not; b serum HER2 ECD decline ≥20 % or not
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s00535-015-1046-3.
Rights and permissions
About this article
Cite this article
Zhou, J., Peng, Z., Liu, Y. et al. Erratum to: Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. J Gastroenterol 51, 509–510 (2016). https://doi.org/10.1007/s00535-016-1186-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-016-1186-0